IRIS
BOCCARDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 33.618
Totale 33.618
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 33.618
Totale 33.618
Salva come PNG Salva come JPEG
Città #
Genova 25.260
Rapallo 3.374
Genoa 2.674
Vado Ligure 2.245
Bordighera 65
Totale 33.618
Salva come PNG Salva come JPEG
Nome #
Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome 196
Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials 169
A Case of Advanced Mucinous Adenocarcinoma of Bladder in an Adult Patient Treated With Capecitabine-Based Chemotherapy and Review of Literature 160
Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. 160
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer 157
Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. 155
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 153
Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy 152
Efficacy of motesanib diphosphate in non-small-cell lung cancer. 149
A Case of Plasmacytoid Variant of Bladder Cancer with a Single Penile Metastasis and a Complete Response to Carboplatin-Based Chemotherapy and Review of the Literature 147
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. 147
Apalutamide treatment and metastasis-free survival in prostate cancer 147
Next Generation Sequencing In Non-Small Cell Lung Cancer: New Avenues Toward The Personalized Medicine. 144
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 141
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma 140
Differential expression of nuclear lamins in normal and cancerous prostate tissues 138
Ovarian ablation in early breast cancer: overview of the randomised trials. 137
Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. 137
Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast 136
Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. 135
Leiomyosarcoma of the broad ligament: a case report and review of literature. 133
Androgen-deprivation therapy is more than palliation in oligometastatic prostate cancer 133
Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case report 132
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma 132
A hnRNP K–AR-related signature reflects progression toward castration-resistant prostate cancer 132
Switching to aromatase inhibitors in early breast cancer. 132
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study 131
Combinations of hormonal therapy and chemotherapy 131
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer 131
Adjuvant therapy for patients with node negative breast cancer. 130
Alternating chemo-radiotherapy in bladder cancer: a conservative approach. 130
Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. 130
Adjuvant chemotherapy of bladder cancer. 130
Effects of three cytokine regimens on hematologic recovery and progenitor cell mobilization after high-dose cyclophosphamide, etoposide, and cisplatin. 130
Communicating cancer diagnosis and prognosis: when the target is the elderly patient-a GIOGer study. 129
Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer. 129
Prognostic factors in patients receiving third-line targeted therapy for metastatic renal cell carcinoma. 127
Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. 127
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy 127
Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery 126
Prognostic variables in localized small cell neuroendocrine carcinoma of the bladder: A population-based study 126
Priming action on progesterone receptor synthesis by estradiol and tamoxifen in the 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinoma. 125
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Long term results of the Italian Tamoxifen Anastrozole trial. 125
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. 124
Re: j. Alfred witjes. A case of abiraterone acetate withdrawal. Eur urol 2013;64:517-8. 124
D-TRP-6-LH-RH treatment of advanced prostatic cancer 124
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials 124
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. 124
Enterolactone in breast cyst fluid: correlation with EGF and breast cancer risk. 123
Paclitaxel plus organoplatins: still the gold standard in advanced ovarian cancer? 123
Chemotherapy with cisplatin and 5-fluorouracil chronomodulated infusion in locally advanced or metastatic/recurrent carcinoma of the cervix. 123
Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: from 223Ra-dichloride to new horizons for therapeutic response assessment 123
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials 123
Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study 123
Management of young women with early breast cancer 123
Somatuline and tamoxifen in postmenopausal breast cancer patients. 122
Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. 122
Oral vinorelbine in the treatment of non-small-cell lung cancer. 122
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. 122
Carboplatin in advanced hormone refractory prostatic cancer patients. 121
Long-term endocrine effects of administration of either a non-steroidal antiandrogen or a luteinizing hormone-releasing hormone agonist in men with prostate cancer. 121
Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer 121
Serum enterolactone levels and the risk of breast cancer in women with palpable cysts. 121
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. 121
Presence and distribution of growth factors in breast cyst fluid. 120
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. 120
Prognostic value of preoperative serum levels of periostin (PN) in early breast cancer (BCa) 120
R75251 in prostate cancer patients in progression after first-line hormonal treatment. 119
Ifosfamide in urologic cancer. 119
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: Meta-analysis of individual patient data from ten randomised trials 119
Italian national consensus conference on prostate cancer screening (Florence, May 17, 2003)--final consensus document. 119
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials 119
Fertility, sexuality and cancer in young adult women 119
Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl) in prostate cancer. An Italian multicentric trial. 118
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: A mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes 117
Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients. 117
Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer. 116
Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. 116
Endothelial cells increase the radiosensitivity of oropharyngeal squamous carcinoma cells in collagen gel 116
Belagenpumatucel-L for the treatment of non-small cell lung cancer 116
Management of breast cancer: Is there a role for Somatostatin and its analogs? 115
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. 115
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. 115
Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis 115
Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial 115
Nafarelin acetate and benign prostatic hyperplasia. 114
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial 114
Periostin: A Novel Prognostic and Therapeutic Target For Genitourinary Cancer? 114
Combination of sorafenib and weekly gemcitabine in patients (pts) with metastatic renal cell Cancer (MRCC): A phase II study, preliminary results 114
Urethral stricture and scrotal abscess: a rare case presentation of penile cancer and review of the literature 114
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer 114
Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy. 114
Phase II study of navelbine in advanced renal cell carcinoma. 113
Prognostic value of cell cycle regulatory proteins in muscle-infiltrating bladder cancer 113
Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study 113
Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer. 113
Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer. 113
Bone metastases from prostate cancer: hormonal therapy 112
Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question! 112
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen. Results of the GROCTA trial. 111
Totale 12.715
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.929
article - articoli 89.449
book - libri 443
conference - conferenze 171
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 8.866
Totale 197.858
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.827 0 0 0 0 0 0 1.478 610 766 1.603 1.062 308
2020/20212.770 153 267 210 287 156 382 102 215 233 284 217 264
2021/20224.214 105 289 202 604 152 290 132 1.154 233 379 96 578
2022/20234.052 409 225 46 383 741 831 7 272 729 30 317 62
2023/20241.832 85 294 46 205 154 317 99 113 84 61 94 280
2024/20252.484 130 458 218 402 719 539 18 0 0 0 0 0
Totale 34.307